CTI Biopharma Corp reports results for the quarter ended in March - Earnings Summary

CTI Biopharma

14/05/2022 11:05

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss
of 37 cents​​ per share for the quarter ended in March. The mean
expectation of five analysts for the quarter was for a loss
of 41 cents per share.
    * Revenue was $2.30 million​;  analysts expected $1.54
million. 
    * CTI Biopharma Corp's reported EPS for the quarter was a
loss
of 37 cents​.
    * The mean earnings estimate of analysts had fallen by
about 67.8%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * CTI Biopharma Corp shares had fallen by 21.6% this
quarter and
gained 47.6% so far this year.
    * The company reported a quarterly loss of $37.18 million.
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $9.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 14 at 10:04 a.m.  ​All
figures in US dollars unless otherwise stated